← Back to screener

Ovid Therapeutics Inc. OVID

Rank #2310 · Nasdaq · $0.5B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
25.0
P/E
-17.9
P/B
5.40
ROE
-30.1%
Op. Margin
-10933.7%
Debt Ratio
27%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -17.9x, P/B 5.40x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -30.1%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 27%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 44.4% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2017–$-0.0B$-0.0B$0.0B–1019
2018–$-0.1B$-0.1B$0.0B–81
2019–$-0.1B$-0.1B$0.1B–11
2020$0.0B$-0.1B$-0.1B$0.0B-486.728
2021$0.0B$-0.1B$-0.1B$0.1B-645.446
2022$0.2B$0.1B$0.1B$0.0B59.634
2023$0.0B$-0.1B$-0.1B$0.2B-3696.413
2024$0.0B$-0.1B$-0.1B$0.1B-15122.743
2025$0.0B$-0.1B$-0.0B$0.1B-10933.727

← See the full screener